The U.S. Department of Health and Human Services (HHS) has rolled out a department-wide plan—Operation Trailblazer—to speed up early-stage prescription drug development amid intensifying competition from China. The blueprint focuses on the first-in-human (FIH) work needed for Investigational New Drug (IND) filings. Among the proposals, HHS seeks clearer FDA expectations for IND data packages to reduce unnecessary documentation, more flexible trial protocol updates, and a pilot model for developers to consult with a network of research institutions ahead of submission. The agency is also testing “rolling submission” pathways to deliver timely guidance to sponsors. The package also addresses clinical trial enrollment logistics, including exploring trial-enrollee stipends, while weighing anti-kickback compliance constraints. The initiative extends a broader policy effort to protect U.S.-based innovation and manufacturing as regulators adapt to a faster global development cadence.